Your session is about to expire
← Back to Search
Radium-223 + Pembrolizumab for Prostate Cancer
Study Summary
This trial is studying the safety and tolerability of an investigational combination of drugs, radium-223 plus pembrolizumab, for the treatment of castration-resistant prostate cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My prostate cancer diagnosis was confirmed through a tissue examination.I have had multiple treatments for my condition.I am 18 years old or older.I meet the specific health and treatment history criteria for the study.My prostate cancer is resistant to hormone therapy and is getting worse.My cancer has spread to my bones, confirmed by a scan.I am fully active or can carry out light work.I am willing to have a bone biopsy before and during the study.My organs are functioning well.I have previously received treatment with radium-223 or PD-1/PD-L1/PD-L2 blockers.My prostate cancer is mainly small cell type.
- Group 1: Radium-223
- Group 2: Pembrolizumab Plus Radium-223
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the primary therapeutic applications of Pembrolizumab?
"Pembrolizumab is widely used for treating malignant neoplasms, as well as more specific conditions such as unresectable melanoma, microsatellite instability high and chemotherapy resistance."
Is this experiment currently accepting new participants?
"According to clinicaltrials.gov, this study is no longer actively searching for patients; the trial was initially posted on June 9th 2017 and last updated on August 31st 2022. Fortunately, there are 2288 other studies that are currently recruiting volunteers."
What is the aggregate number of participants in this clinical experiment?
"This trial is no longer actively seeking participants. It was initially announced on the 9th of June 2017 and last updated on 31st August 2022. For those looking for alternate studies, there are 1,315 active trials recruiting prostate cancer patients and a further 973 studies with Pembrolizumab that need volunteers."
Has the FDA sanctioned Pembrolizumab for widespread use?
"The safety of Pembrolizumab was assessed with a score of 2, as it is currently in Phase 2 trials and there are data confirming its safety but none affirming efficacy."
What objectives are being sought through the execution of this research?
"The primary end-point of this medical trial, which is to be documented over a two month period, evaluates the level of immune cell infiltration. Secondary objectives encompass overall survival (from randomization/registration until death from any cause), incidence of treatment associated adverse events graded as 3 or higher on NCI CTCAE version 4.0 scale and progression free survival rate determined by RECIST 1.1 criteria."
What precedent has been documented regarding research on Pembrolizumab?
"Currrently, 973 active clinical trials are running for pembrolizumab with a hefty 126 of them in their concluding phase. Most experiments take place in Houston but there remains 36146 different locations looking to trial this drug."
Share this study with friends
Copy Link
Messenger